APA (7th ed.) Citation

Ding, J., Xu, K., Niu, Y., Qin, Y., Shen, H., Wang, Y., . . . Zhu, A. X. (2024). Plonmarlimab, a novel anti‐GM‐CSF blocking antibody, ameliorates disease progression in the pre‐clinical model of macrophage activation syndrome. Immunology, 173(3), 552. https://doi.org/10.1111/imm.13842

Chicago Style (17th ed.) Citation

Ding, Jian, et al. "Plonmarlimab, a Novel Anti‐GM‐CSF Blocking Antibody, Ameliorates Disease Progression in the Pre‐clinical Model of Macrophage Activation Syndrome." Immunology 173, no. 3 (2024): 552. https://doi.org/10.1111/imm.13842.

MLA (9th ed.) Citation

Ding, Jian, et al. "Plonmarlimab, a Novel Anti‐GM‐CSF Blocking Antibody, Ameliorates Disease Progression in the Pre‐clinical Model of Macrophage Activation Syndrome." Immunology, vol. 173, no. 3, 2024, p. 552, https://doi.org/10.1111/imm.13842.